BioInvent International Stock

BioInvent International EBIT per Employee

The EBIT per Employee of BioInvent International (BINV.ST) as of Aug 6, 2026 is -4.81 M SEK. In the previous year, EBIT per Employee was -6.45 M SEK — a change of -25.40% (higher).

EBIT per Employee

-4.81 MSEK

YoY

-25.40%

Last updated:

EBIT per Employee of BioInvent International is 2026 -4.81 M SEK. EBIT per Employee of BioInvent International was 2025 -6.45 M SEK. It decreases by -25.40% higher compared to the previous year.
Access this data via the Eulerpool API

BioInvent International Stock analysis

What does BioInvent International do? BioInvent International AB is a Swedish biopharmaceutical company specializing in the discovery and development of therapeutic antibodies. It was founded in 1986 and is headquartered in Lund, Sweden. BioInvent conducts research and development activities in the fields of immuno-oncology, inflammatory diseases, and fibrosis. BioInvent International is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioInvent International stock

EBIT per Employee of BioInvent International is -4.81 M SEK in 2026.

EBIT per Employee of BioInvent International changed from -6.45 M SEK to -4.81 M SEK, representing a -25.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee BioInvent International since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's BioInvent International historically and in real time.

Access this data via the Eulerpool API

Workforce — BioInvent International

All Key Metrics — BioInvent International